BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 24474262)

  • 1. Pretreatment Dynamic Susceptibility Contrast MRI Perfusion in Glioblastoma: Prediction of EGFR Gene Amplification.
    Gupta A; Young RJ; Shah AD; Schweitzer AD; Graber JJ; Shi W; Zhang Z; Huse J; Omuro AM
    Clin Neuroradiol; 2015 Jun; 25(2):143-50. PubMed ID: 24474262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers.
    Jain R; Poisson L; Narang J; Gutman D; Scarpace L; Hwang SN; Holder C; Wintermark M; Colen RR; Kirby J; Freymann J; Brat DJ; Jaffe C; Mikkelsen T
    Radiology; 2013 Apr; 267(1):212-20. PubMed ID: 23238158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebral blood volume calculated by dynamic susceptibility contrast-enhanced perfusion MR imaging: preliminary correlation study with glioblastoma genetic profiles.
    Ryoo I; Choi SH; Kim JH; Sohn CH; Kim SC; Shin HS; Yeom JA; Jung SC; Lee AL; Yun TJ; Park CK; Park SH
    PLoS One; 2013; 8(8):e71704. PubMed ID: 23977117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting epidermal growth factor receptor gene amplification status in glioblastoma multiforme by quantitative enhancement and necrosis features deriving from conventional magnetic resonance imaging.
    Dong F; Zeng Q; Jiang B; Yu X; Wang W; Xu J; Yu J; Li Q; Zhang M
    Medicine (Baltimore); 2018 May; 97(21):e10833. PubMed ID: 29794775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients.
    Figueroa JM; Skog J; Akers J; Li H; Komotar R; Jensen R; Ringel F; Yang I; Kalkanis S; Thompson R; LoGuidice L; Berghoff E; Parsa A; Liau L; Curry W; Cahill D; Bettegowda C; Lang FF; Chiocca EA; Henson J; Kim R; Breakefield X; Chen C; Messer K; Hochberg F; Carter BS
    Neuro Oncol; 2017 Oct; 19(11):1494-1502. PubMed ID: 28453784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diffusion and perfusion MRI may predict EGFR amplification and the TERT promoter mutation status of IDH-wildtype lower-grade gliomas.
    Park YW; Ahn SS; Park CJ; Han K; Kim EH; Kang SG; Chang JH; Kim SH; Lee SK
    Eur Radiol; 2020 Dec; 30(12):6475-6484. PubMed ID: 32785770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic Contrast-Enhanced T1-Weighted Perfusion Magnetic Resonance Imaging Identifies Glioblastoma Immunohistochemical Biomarkers via Tumoral and Peritumoral Approach: A Pilot Study.
    Ozturk K; Soylu E; Tolunay S; Narter S; Hakyemez B
    World Neurosurg; 2019 Aug; 128():e195-e208. PubMed ID: 31003026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between dynamic susceptibility contrast perfusion MRI and genomic alterations in glioblastoma.
    Ozturk K; Soylu E; Cayci Z
    Neuroradiology; 2021 Nov; 63(11):1801-1810. PubMed ID: 33738509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perfusion MRI (dynamic susceptibility contrast imaging) with different measurement approaches for the evaluation of blood flow and blood volume in human gliomas.
    Thomsen H; Steffensen E; Larsson EM
    Acta Radiol; 2012 Feb; 53(1):95-101. PubMed ID: 22114021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma.
    Tykocinski ES; Grant RA; Kapoor GS; Krejza J; Bohman LE; Gocke TA; Chawla S; Halpern CH; Lopinto J; Melhem ER; O'Rourke DM
    Neuro Oncol; 2012 May; 14(5):613-23. PubMed ID: 22492960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts.
    Johnson H; Del Rosario AM; Bryson BD; Schroeder MA; Sarkaria JN; White FM
    Mol Cell Proteomics; 2012 Dec; 11(12):1724-40. PubMed ID: 22964225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging.
    Barajas RF; Chang JS; Segal MR; Parsa AT; McDermott MW; Berger MS; Cha S
    Radiology; 2009 Nov; 253(2):486-96. PubMed ID: 19789240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential role of preoperative conventional MRI including diffusion measurements in assessing epidermal growth factor receptor gene amplification status in patients with glioblastoma.
    Young RJ; Gupta A; Shah AD; Graber JJ; Schweitzer AD; Prager A; Shi W; Zhang Z; Huse J; Omuro AM
    AJNR Am J Neuroradiol; 2013 Dec; 34(12):2271-7. PubMed ID: 23811973
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Bakas S; Akbari H; Pisapia J; Martinez-Lage M; Rozycki M; Rathore S; Dahmane N; O'Rourke DM; Davatzikos C
    Clin Cancer Res; 2017 Aug; 23(16):4724-4734. PubMed ID: 28428190
    [No Abstract]   [Full Text] [Related]  

  • 15. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.
    Feldkamp MM; Lala P; Lau N; Roncari L; Guha A
    Neurosurgery; 1999 Dec; 45(6):1442-53. PubMed ID: 10598712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas.
    Biernat W; Huang H; Yokoo H; Kleihues P; Ohgaki H
    Brain Pathol; 2004 Apr; 14(2):131-6. PubMed ID: 15193025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.
    Sepúlveda-Sánchez JM; Vaz MÁ; Balañá C; Gil-Gil M; Reynés G; Gallego Ó; Martínez-García M; Vicente E; Quindós M; Luque R; Ramos A; Ruano Y; Pérez-Segura P; Benavides M; Sánchez-Gómez P; Hernández-Laín A
    Neuro Oncol; 2017 Oct; 19(11):1522-1531. PubMed ID: 28575464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRI perfusion in determining pseudoprogression in patients with glioblastoma.
    Young RJ; Gupta A; Shah AD; Graber JJ; Chan TA; Zhang Z; Shi W; Beal K; Omuro AM
    Clin Imaging; 2013; 37(1):41-9. PubMed ID: 23151413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic Alterations of Epidermal Growth Factor Receptor in Glioblastoma: The Usefulness of Immunohistochemistry.
    Lee M; Kang SY; Suh YL
    Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):589-598. PubMed ID: 29912767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of survival in patients affected by glioblastoma: histogram analysis of perfusion MRI.
    Romano A; Pasquini L; Di Napoli A; Tavanti F; Boellis A; Rossi Espagnet MC; Minniti G; Bozzao A
    J Neurooncol; 2018 Sep; 139(2):455-460. PubMed ID: 29721752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.